London, UK and Montreal, Canada, November 8, 2017 (Newswire) –Fortuna Fix (“Fortuna”), a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells (autologous) produced by direct reprogramming (“drNPCs”
[Read more…]
Breakthrough Regenerative Therapeutics Company Establishes Scientific Advisory Board
Montreal, Canada, May 4, 2017 – Fortuna Fix Inc., (“Fortuna”), a private, clinical-stage biotech company is aiming to be the first to eliminate the need for embryonic and fetal stem cells by using direct reprogramming of autologous cells to treat neurodegenerative diseases. Fortuna announced today the launch of its Scientific Advisory Board (“SAB”) with Professor Michael Fehlings, MD, PhD, Father Kevin FitzGerald, S.J., PhD, COL (R) Dallas Hack, MD, MPH, and Professor James Giordano, PhD. [Read more…]